108 related articles for article (PubMed ID: 6091827)
1. Leukotriene B4-like material in scale of psoriatic skin lesions.
Brain SD; Camp RD; Cunningham FM; Dowd PM; Greaves MW; Black AK
Br J Pharmacol; 1984 Sep; 83(1):313-7. PubMed ID: 6091827
[TBL] [Abstract][Full Text] [Related]
2. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis.
Brain S; Camp R; Dowd P; Black AK; Greaves M
J Invest Dermatol; 1984 Jul; 83(1):70-3. PubMed ID: 6330213
[TBL] [Abstract][Full Text] [Related]
3. Psoriatic skin lesions contain a novel lipid neutrophil chemokinetic compound which is distinct from known chemoattractant eicosanoids.
Camp RD; Cunningham FM; Fincham NJ; Greaves MW; Kobza Black A; Mallet AI; Woollard PM
Br J Pharmacol; 1988 Aug; 94(4):1043-50. PubMed ID: 3061542
[TBL] [Abstract][Full Text] [Related]
4. Eicosanoids in acute and chronic psoriatic lesions: leukotriene B4, but not 12-hydroxy-eicosatetraenoic acid, is present in biologically active amounts in acute guttate lesions.
Fogh K; Herlin T; Kragballe K
J Invest Dermatol; 1989 Jun; 92(6):837-41. PubMed ID: 2542417
[TBL] [Abstract][Full Text] [Related]
5. Psoriatic skin lesions contain biologically active amounts of an interleukin 1-like compound.
Camp RD; Fincham NJ; Cunningham FM; Greaves MW; Morris J; Chu A
J Immunol; 1986 Dec; 137(11):3469-74. PubMed ID: 3491138
[TBL] [Abstract][Full Text] [Related]
6. Leukotrienes C4 and D4 in psoriatic skin lesions.
Brain SD; Camp RD; Black AK; Dowd PM; Greaves MW; Ford-Hutchinson AW; Charleson S
Prostaglandins; 1985 Apr; 29(4):611-9. PubMed ID: 2988023
[TBL] [Abstract][Full Text] [Related]
7. A study of the photodegradation of leukotriene B4 by ultraviolet irradiation (UVB, UVA).
Millar B; Green C; Ferguson J; Raffle EJ; Macleod TM
Br J Dermatol; 1989 Feb; 120(2):145-52. PubMed ID: 2538137
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of leukotriene B4 in the scale extracts of psoriasis and inflammatory pustular dermatoses. Correlation with leukocyte chemotactic activity and C5a anaphylatoxin.
Takematsu H; Terui T; Tagami H
Acta Derm Venereol; 1986; 66(1):6-10. PubMed ID: 2424218
[TBL] [Abstract][Full Text] [Related]
9. Leukotriene B4 receptors on neutrophils in patients with psoriasis and atopic eczema.
Meier F; Gross E; Klotz KN; Ruzicka T
Skin Pharmacol; 1989; 2(2):61-7. PubMed ID: 2560652
[TBL] [Abstract][Full Text] [Related]
10. LTA4 hydrolase in human skin: decreased activity, but normal concentration in lesional psoriatic skin. Evidence for different LTA4 hydrolase activity in human lymphocytes and human skin.
Iversen L; Deleuran B; Hoberg AM; Kragballe K
Arch Dermatol Res; 1996 May; 288(5-6):217-24. PubMed ID: 8738563
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil chemoattractant and IL-1-like activity in samples from psoriatic skin lesions. Further characterization.
Fincham NJ; Camp RD; Gearing AJ; Bird CR; Cunningham FM
J Immunol; 1988 Jun; 140(12):4294-9. PubMed ID: 3286771
[TBL] [Abstract][Full Text] [Related]
12. Identification of chemotactic lipoxygenase products of arachidonate metabolism in psoriatic skin.
Grabbe J; Czarnetzki BM; Rosenbach T; Mardin M
J Invest Dermatol; 1984 May; 82(5):477-9. PubMed ID: 6096449
[TBL] [Abstract][Full Text] [Related]
13. Reduction of leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukocytes by methotrexate in psoriasis.
Lammers AM; van de Kerkhof PC; Mier PD
Br J Dermatol; 1987 May; 116(5):667-71. PubMed ID: 3036194
[TBL] [Abstract][Full Text] [Related]
14. The effect of etretinate on the cyclo-oxygenase and lipoxygenase products of arachidonic acid metabolism in psoriatic skin.
Wong E; Barr RM; Brain SD; Greaves MW; Olins LA; Mallet AI
Br J Clin Pharmacol; 1984 Oct; 18(4):523-7. PubMed ID: 6091710
[TBL] [Abstract][Full Text] [Related]
15. Leukotriene B4 fails to induce penetration of polymorphonuclear leukocytes into psoriatic lesions.
Lammers AM; van de Kerkhof PC
Br J Dermatol; 1987 Nov; 117(5):541-4. PubMed ID: 2825753
[TBL] [Abstract][Full Text] [Related]
16. Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasis.
Wong E; Barr RM; Cunningham FM; Mistry K; Woollard PM; Mallet AI; Greaves MW
Br J Clin Pharmacol; 1986 Dec; 22(6):627-32. PubMed ID: 3032226
[TBL] [Abstract][Full Text] [Related]
17. The identification of hydroxy fatty acids in psoriatic skin.
Camp RD; Mallet AI; Woollard PM; Brain SD; Black AK; Greaves MW
Prostaglandins; 1983 Sep; 26(3):431-47. PubMed ID: 6419288
[TBL] [Abstract][Full Text] [Related]
18. Retinoids are potent inhibitors of the generation of rat leukocyte leukotriene B4-like activity in vitro.
Bray MA
Eur J Pharmacol; 1984 Feb; 98(1):61-7. PubMed ID: 6325211
[TBL] [Abstract][Full Text] [Related]
19. 5-Lipoxygenase activation in psoriasis: a dead issue?
Ford-Hutchinson AW
Skin Pharmacol; 1993; 6(4):292-7. PubMed ID: 8198815
[TBL] [Abstract][Full Text] [Related]
20. Epicutaneous application of leukotriene B4 induces patterns of tenascin and a heparan sulfate proteoglycan epitope that are typical for psoriatic lesions.
Seyger MM; van Pelt JP; van den Born J; Latijnhouwers MA; de Jong EM
Arch Dermatol Res; 1997 May; 289(6):331-6. PubMed ID: 9209678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
